Citations (140)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Rohit K Jain & Guru Sonpavde. (2020) Neoadjuvant therapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy 20:7, pages 603-614.
Read now
Read now
Vivek Narayan & David Vaughn. (2015) Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Expert Opinion on Drug Metabolism & Toxicology 11:5, pages 731-742.
Read now
Read now
Prakash Vishnu, Jacob Mathew & Winston W Tan. (2011) Current therapeutic strategies for invasive and metastatic bladder cancer. OncoTargets and Therapy 4, pages 97-113.
Read now
Read now
Ranveig Røtterud, Per-Uno Malmström, Rolf Wahlqvist & Kristin A. Taskén. (2010) The star chart to Ta bladder cancer: An unsophisticated analysis of two-dimensional gel electrophoresis proteome maps. Scandinavian Journal of Urology and Nephrology 44:2, pages 76-83.
Read now
Read now
Faysal A Yafi & Wassim Kassouf. (2009) Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?. Expert Review of Anticancer Therapy 9:6, pages 747-752.
Read now
Read now
Peter E Clark. (2009) Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy 9:6, pages 821-830.
Read now
Read now
Guru Sonpavde, Gilad E Amiel, Martha P Mims, Teresa G Hayes & Seth P Lerner. (2008) Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opinion on Pharmacotherapy 9:11, pages 1885-1893.
Read now
Read now
Jonathan E Rosenberg. (2007) Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy 7:12, pages 1729-1736.
Read now
Read now
Danish Mazhar, Nasim Ali & Sarah Ngan. (2007) Neoadjuvant Chemotherapy for Bladder Transitional Cell Carcinoma: A New Standard of Care?. Future Oncology 3:1, pages 5-8.
Read now
Read now
Sandy Srinivas & Natalia Colocci. (2006) Nonplatinum therapy in advanced bladder cancer. Expert Review of Anticancer Therapy 6:6, pages 887-894.
Read now
Read now
Gilad E Amiel & Seth P Lerner. (2006) Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Review of Anticancer Therapy 6:2, pages 281-291.
Read now
Read now
Aristotle Bamias & Meletios A Dimopoulos. (2005) Neoadjuvant chemotherapy in invasive bladder cancer. Expert Review of Anticancer Therapy 5:6, pages 993-1000.
Read now
Read now
Judi C Herring & Ashish M Kamat. (2004) Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Review of Anticancer Therapy 4:6, pages 1047-1056.
Read now
Read now
Articles from other publishers (127)
Hasan Yılmaz, Kerem Teke, Evren Süer, Volkan İzol, Hacı Murat Akgül & İsmail Selvi. (2024) Does neo-adjuvant chemotherapy improve the negative effect of lymphovascular invasion in survival after radical cystectomy?. Urologic Oncology: Seminars and Original Investigations 42:2, pages 30.e1-30.e7.
Crossref
Crossref
Nishita Tripathi, Gliceida Galarza Fortuna, Georges Gebrael, Emre Dal, Vinay Mathew Thomas, Sumati Gupta & Umang Swami. (2024) Predictors of response to neoadjuvant therapy in urothelial cancer. Critical Reviews in Oncology/Hematology 194, pages 104236.
Crossref
Crossref
Homin Kang, Jungyo Suh, Dalsan You, In Gab Jeong, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn & Bumjin Lim. (2024) Risk factors for failing to complete gemcitabine–cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients. Investigative and Clinical Urology 65.
Crossref
Crossref
Sujit S. Nair, Dimple Chakravarty, Vaibhav Patel, Nina Bhardwaj & Ashutosh K. Tewari. (2023) Genitourinary cancer neoadjuvant therapies: current and future approaches. Trends in Cancer 9:12, pages 1041-1057.
Crossref
Crossref
Krystian Kaczmarek, Bartosz Małkiewicz, Karolina Skonieczna-Żydecka & Artur Lemiński. (2023) Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes. Cancers 15:19, pages 4901.
Crossref
Crossref
Abdulmajeed Aydh, Reza Sari Motlagh, Abdulaziz Alamri, Takafumi Yanagisawa, Adil Ayed, Pawel Rajwa, Ekaterina Laukhtina, Saeed M. Alasiri, Tatsushi Kawada, Hadi Mostafai, Abdulelah Ayidh, Maximilian Pallauf, Frederik König, Mohammad Abufaraj, Pierre I. Karakiewicz & Shahrokh F. Shariat. (2023) Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes. World Journal of Urology 41:8, pages 2185-2194.
Crossref
Crossref
Lisa M. C. van Hoogstraten, Calvin C. O. Man, J. Alfred Witjes, Richard P. Meijer, Sasja F. Mulder, Tineke J. Smilde, Theodora M. Ripping, Lambertus A. Kiemeney, Katja K. H. Aben, J. Alfred Witjes, Theodora M. Ripping, Joost L. Boormans, Catharina A. Goossens-Laan, Antoine G. van der Heijden, Michiel S. van der Heijden, Sipke Helder, Tom J. N. Hermans, Maarten C. C. M. Hulshof, Anna M. Leliveld, Geert J. L. H. van Leenders, Richard P. Meijer, Reindert J. A. van Moorselaar, Juus L. Noteboom, Jorg R. Oddens, Theo M. de Reijke, Bas W. G. van Rhijn, Joep G. H. van Roermund, Guus W. J. Venderbosch & Bart P. Wijsman. (2023) Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer. World Journal of Urology 41:7, pages 1837-1845.
Crossref
Crossref
Kyung Hwan Kim, Hye Won Lee, Hong Koo Ha & Ho Kyung Seo. (2023) Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies. Investigative and Clinical Urology 64:3, pages 202.
Crossref
Crossref
Christina Tanem Møller, Nathalie C. Støer, Augun Blindheim, Viktor Berge, Gunnar Tafjord, Sophie D. Fosså & Bettina Kulle Andreassen. (2022) Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study. BMC Cancer 22:1.
Crossref
Crossref
Yupeng Guo, Jing Dong, Tao Ji, Xiaoxia Li, Shengzhong Rong & Hongjun Guan. (2022) A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy. Aging.
Crossref
Crossref
Tarik Benidir, Zaeem Lone, Ao Zhang, Amy S. Nowacki, Carlos Munoz-Lopez, Pranay Hegde, Kevin Fung, Jesse Fajnzylber, Robert Abouassaly, Ryan Berglund, Eric A. Klein, Mohammed Eltemamy, Jihad Kaouk, Christopher J. Weight, Nima Almassi, Georges Pascal-Haber & Byron H. Lee. (2022) Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy. Urology 168, pages 137-142.
Crossref
Crossref
Shuai Liu, Yu Yao, Fengju Guan, Lijiang Sun & Guiming Zhang. (2022) Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Disease Markers 2022, pages 1-11.
Crossref
Crossref
Maria Lucia Iacovino, Chiara Carmen Miceli, Marco De Felice, Biagio Barone, Luca Pompella, Francesco Chiancone, Erika Di Zazzo, Giuseppe Tirino, Carminia Maria Della Corte, Ciro Imbimbo, Ferdinando De Vita & Felice Crocetto. (2022) Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 23:3, pages 1133.
Crossref
Crossref
Brendan J. Guercio & Gopa Iyer. 2022. Urologic Oncology. Urologic Oncology
349
379
.
Tarik Benidir, Jaime Herrera‐Caceres, Christopher Wallis, Katherine Lajkosz & Neil Fleshner. (2021) Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer. Cancer Medicine 10:8, pages 2636-2644.
Crossref
Crossref
Eijiro Okajima, Mitsuru Tomizawa, Keiji Shimada, Takahito Negishi, Naotaka Nishiyama & Hiroshi Kitamura. (2020) D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy. Urologic Oncology: Seminars and Original Investigations 38:10, pages 797.e7-797.e13.
Crossref
Crossref
Vaibhav G. Patel, William K. Oh & Matthew D. Galsky. (2020) Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA: A Cancer Journal for Clinicians 70:5, pages 404-423.
Crossref
Crossref
Miguel Cajipe, Hanzhang Wang, Ahmed Elshabrawy, Dharam Kaushik, Michael Liss, Robert Svatek, Shenghui Wu, Wasim H. Chowdhury, Chethan Ramamurthy & Ahmed M. Mansour. (2020) Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only. Urologic Oncology: Seminars and Original Investigations 38:4, pages 231-239.
Crossref
Crossref
Angela B. Smith, Arjun V. Balar, Matthew I. Milowsky & Ronald C. Chen. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1382
1400.e4
.
Michael A. Feuerstein, Leah Goldstein, Brieyona Reaves, Arony Sun, Michael Goltzman, Bradley A. Morganstern, Ahmad Shabsigh, Dean F. Bajorin, Jonathan E. Rosenberg, S. Machele Donat, Harry W. Herr, Vincent P. Laudone, Thomas M. Atkinson, Yuelin Li, Guido Dalbagni, Bruce Rapkin & Bernard H. Bochner. (2019) Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. World Journal of Urology 37:11, pages 2401-2407.
Crossref
Crossref
Jennifer Tse, Rashed Ghandour, Nirmish Singla & Yair Lotan. (2019) Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. International Journal of Molecular Sciences 20:4, pages 793.
Crossref
Crossref
Lee A. Hugar, Jonathan G. Yabes, Robert M. TurnerIIII, Mina M. Fam, Leonard J. Appleman, Benjamin J. Davies & Bruce L. Jacobs. (2019) Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis. Urology 124, pages 191-197.
Crossref
Crossref
Albert Font, Raquel Luque, José Carlos Villa, Montse Domenech, Sergio Vázquez, Enrique Gallardo, Juan Antonio Virizuela, Carmen Beato, Rafael Morales-Barrera, Antoni Gelabert, Sonia Maciá, Javier Puente, Gustavo Rubio, Xavier Maldonado, Begoña Perez-Valderrama, Alvaro Pinto, Ovidio Fernández Calvo, Enrique Grande, Javier Garde-Noguera, Eva Fernández-Parra & José Ángel Arranz. (2019) The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Targeted Oncology 14:1, pages 15-32.
Crossref
Crossref
Gautier Marcq, Edouard Jarry, Idir Ouzaid, Jean-François Hermieu, François Henon, Jean-Christophe Fantoni & Evanguelos Xylinas. (2019) Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. Therapeutic Advances in Urology 11, pages 175628721882367.
Crossref
Crossref
G. Pignot, N. Houédé, M. Roumiguié, F. Audenet, S. Brunelle, P. Colin, E. Compérat, S. Larré, A. Masson-Lecomte, Y. Neuzillet, E. Xylinas, A. Méjean & M. Rouprêt. (2018) Pièce opératoire ypT0N0 après séquence chimiothérapie néo-adjuvante – cystectomie pour TVIM : épidémiologie et impact pronostique. Une mise au point du CCAFU Vessie. Progrès en Urologie 28:12, pages 567-574.
Crossref
Crossref
Tom J.N. Hermans, Charlotte S. Voskuilen, Michiel S. van der Heijden,Bernd J. Schmitz-Dräger, Wassim Kassouf, Roland Seiler, Ashish M. Kamat, Petros Grivas, Anne E. Kiltie, Peter C. Black & Bas W.G. van Rhijn. (2018) Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urologic Oncology: Seminars and Original Investigations 36:9, pages 413-422.
Crossref
Crossref
Joachim Mathes, Jens Bedke, Arnulf Stenzl & Tilman Todenhöfer. (2018) Urothelkarzinom der Harnblase: Aktuelles zur Systemtherapie. InFo Onkologie 21:5, pages 46-54.
Crossref
Crossref
William Tabayoyong, Roger Li, Jianjun Gao & Ashish Kamat. (2018) Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urologic Clinics of North America 45:2, pages 155-167.
Crossref
Crossref
Nawar Hanna, Quoc-Dien Trinh, Thomas Seisen, Malte W. Vetterlein, Jesse Sammon, Mark A. Preston, Stuart R. Lipsitz, Joaquim Bellmunt, Mani Menon, Toni K. Choueiri & Firas Abdollah. (2018) Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology 1:1, pages 83-90.
Crossref
Crossref
Günter Niegisch & Peter Albers. 2018. Robotic Urology. Robotic Urology
241
248
.
Phillip J. Gray, William U. Shipley & Jason A. Efstathiou. 2017. Clinical Radiation Oncology. Clinical Radiation Oncology
481
496
.
Samuel A. Funt & Jonathan E. Rosenberg. (2016) Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nature Reviews Clinical Oncology 14:4, pages 221-234.
Crossref
Crossref
Friedrich-Carl von Rundstedt, Douglas A. Mata, Oleksandr N. Kryvenko, Anup A. Shah, Iny Jhun & Seth P. Lerner. (2017) Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study. Bladder Cancer 3:1, pages 35-44.
Crossref
Crossref
Ming Yin, Monika Joshi, Richard P. Meijer, Michael Glantz, Sheldon Holder, Harold A. Harvey, Matthew Kaag, Elisabeth E. Fransen van de Putte, Simon Horenblas & Joseph J. Drabick. (2016) Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. The Oncologist 21:6, pages 708-715.
Crossref
Crossref
Oktay Üçer. (2016) The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. EMJ Urology, pages 88-93.
Crossref
Crossref
Jana Katolická. (2016) Current position of chemotherapy in treating bladder cancer. Urologie pro praxi 17:2, pages 64-68.
Crossref
Crossref
Roger Chou, Shelley S. Selph, David I. Buckley, Katie S. Gustafson, Jessica C. Griffin, Sara E. Grusing & John L. Gore. (2016) Treatment of muscle‐invasive bladder cancer: A systematic review. Cancer 122:6, pages 842-851.
Crossref
Crossref
Hyung Suk Kim, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim & Ja Hyeon Ku. (2016) Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis. Clinical Cancer Research 22:5, pages 1086-1094.
Crossref
Crossref
Venkata K. Pokuri, Johar R. Syed, Zhengyu Yang, Erinn P. Field, Susanna Cyriac, Roberto Pili, Ellis Glenn Levine, Gissou Azabdaftari, Donald L. Trump, Khurshid Guru & Saby George. (2016) Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Clinical Genitourinary Cancer 14:1, pages e59-e65.
Crossref
Crossref
Samer L. Traboulsi & Wassim Kassouf. (2016) A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer. Urology Practice 3:1, pages 41-49.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
886
911
.
Jason A. Efstathiou & Anthony L. Zietman. 2016. Clinical Radiation Oncology. Clinical Radiation Oncology
1096
1120.e6
.
Patrizia Trenta, Fabio Calabrò, Linda Cerbone & Cora N. Sternberg. (2016) Chemotherapy for Muscle-Invasive Bladder Cancer. Current Treatment Options in Oncology 17:1.
Crossref
Crossref
Vicente Guillem, Miguel Angel Climent, Javier Cassinello, Emilio Esteban, Daniel Castellano, José Luis González-Larriba, Pablo Maroto & Carlos Camps. (2015) Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urology 15:1.
Crossref
Crossref
Hayley Knollman, J. Luke Godwin, Rishi Jain, Yu-Ning Wong, Elizabeth R. Plimack & Daniel M. Geynisman. (2015) Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Therapeutic Advances in Urology 7:6, pages 312-330.
Crossref
Crossref
Richard P. Meijer. (2015) Chemoradiatie bij het spierinvasieve blaascarcinoomChemoradiation for muscle invasive bladder cancer. Tijdschrift voor Urologie 5:8, pages 210-214.
Crossref
Crossref
Shahrokh F Shariat & Evanguelos XylinasGuilherme Godoy & Guru Sonpavde. 2015. Advances in Bladder Cancer Management. Advances in Bladder Cancer Management
142
156
.
Yinghui WeiPatrick RoystonJayne F. TierneyMahesh K. B. Parmar. (2015) Meta‐analysis of time‐to‐event outcomes from randomized trials using restricted mean survival time: application to individual participant data. Statistics in Medicine 34:21, pages 2881-2898.
Crossref
Crossref
Jan K. Rudzinski, Naveen S. Basappa & Scott North. (2015) Perioperative chemotherapy for muscle invasive bladder cancer. Current Opinion in Supportive & Palliative Care 9:3, pages 249-254.
Crossref
Crossref
David I. Quinn & Cora N. Sternberg. 2015. Bladder cancer. Bladder cancer
284
294
.
Lior Z. Braunstein, William U. Shipley, Nicholas D. James, Andrea B. Apolo & Jason A. Efstathiou. 2015. Bladder cancer. Bladder cancer
221
232
.
Jeffrey J. Leow, André P. Fay, Stephanie A. Mullane & Joaquim Bellmunt. (2015) Perioperative Therapy for Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America 29:2, pages 301-318.
Crossref
Crossref
S. Terrisse, L. Doucet, D. Pouessel, H. Gauthier, C. le Maignan, L. Teixeira, C. Pfister & S. Culine. (2015) Quelle chimiothérapie périopératoire pour les tumeurs de vessie infiltrant le muscle ?Which is the best perioperative chemotherapy for muscle invasive bladder cancer?. Oncologie 17:4, pages 165-169.
Crossref
Crossref
Gautam Jha, Guru Sonpavde & Zeeshan Ahmad. 2015. Management of Bladder Cancer. Management of Bladder Cancer
387
403
.
Faysal A. Yafi, Armen G. Aprikian, Joseph L. Chin, Yves Fradet, Jonathan Izawa, Eric Estey, Adrian Fairey, Ricardo Rendon, Ilias Cagiannos, Louis Lacombe, Jean-Baptiste Lattouf, Fred Saad, David Bell, Darrel Drachenberg & Wassim Kassouf. (2013) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World Journal of Urology 32:5, pages 1295-1301.
Crossref
Crossref
David C. Johnson, Matthew E. Nielsen, Jonathan Matthews, Michael E. Woods, Eric M. Wallen, Raj S. Pruthi, Matthew I. Milowsky & Angela B. Smith. (2014) Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU International 114:2, pages 221-228.
Crossref
Crossref
H. Kitamura, T. Tsukamoto, T. Shibata, N. Masumori, H. Fujimoto, Y. Hirao, K. Fujimoto, Y. Kitamura, Y. Tomita, K. Tobisu, M. Niwakawa, S. Naito, M. Eto & Y. Kakehi. (2014) Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Annals of Oncology 25:6, pages 1192-1198.
Crossref
Crossref
Matthew Mossanen, Franklin Lee, Heather Cheng, William Harris, Jaideep Shenoi, Song Zhao, Junfeng Wang, Thomas Champion, Jason Izard, John L. Gore, Michael P. Porter, Evan Y. Yu & Jonathan L. Wright. (2014) Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. Clinical Genitourinary Cancer 12:3, pages 210-213.
Crossref
Crossref
Hugh J. Lavery, Kristian D. Stensland, Guenter Niegisch, Peter Albers & Michael J. Droller. (2014) Pathological T0 Following Radical Cystectomy with or without Neoadjuvant Chemotherapy: A Useful Surrogate. Journal of Urology 191:4, pages 898-906.
Crossref
Crossref
Faysal A. Yafi, Simon Tanguay, Ricardo Rendon, Niels Jacobsen, Adrian Fairey, Jonathan Izawa, Anil Kapoor, Peter Black, Louis Lacombe, Joe Chin, Alan So, Jean-Baptiste Lattouf, David Bell, Yves Fradet, Fred Saad, Edward Matsumoto, Darrel Drachenberg, Ilias Cagiannos & Wassim Kassouf. (2014) Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. Urologic Oncology: Seminars and Original Investigations 32:1, pages 31.e17-31.e24.
Crossref
Crossref
Angela Smith, Arjun V. Balar, Matthew I. Milowsky & Ronald C. Chen. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1445
1462.e4
.
J.K. Aronson. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
821
861
.
Nobuaki Matsubara, Hirofumi Mukai, Yoichi Naito, Masahiko Nezu & Kuniaki Itoh. (2012) Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle‐invasive bladder cancer. Asia-Pacific Journal of Clinical Oncology 9:4, pages 310-317.
Crossref
Crossref
Christopher M Tully, Gopa Iyer & Dean F Bajorin. (2013) Neoadjuvant chemotherapy in bladder cancer. Clinical Investigation 3:10, pages 991-1002.
Crossref
Crossref
Günter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland & Peter Albers. (2013) Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?. European Urology 64:3, pages 355-357.
Crossref
Crossref
Shilpa GuptaAmit Mahipal. (2013) Role of Systemic Chemotherapy in Urothelial Urinary Bladder Cancer. Cancer Control 20:3, pages 200-210.
Crossref
Crossref
Laura S. Mertens, Annemarie Fioole-Bruining, Bas W.G. van Rhijn, J. Martijn Kerst, André M. Bergman, Wouter V. Vogel, Erik Vegt & Simon Horenblas. (2013) FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer. Journal of Urology 189:5, pages 1687-1691.
Crossref
Crossref
R.P. Meijer, J.A. Nieuwenhuijzen, W. Meinhardt, A. Bex, H.G. van der Poel, B.W. van Rhijn, J.M. Kerst, A.M. Bergman, E. van Werkhoven & S. Horenblas. (2013) Response to induction chemotherapy and surgery in non-organ confined bladder cancer: A single institution experience. European Journal of Surgical Oncology (EJSO) 39:4, pages 365-371.
Crossref
Crossref
Cora N. Sternberg, Joaquim Bellmunt, Guru Sonpavde, Arlene O. Siefker-Radtke, Walter M. Stadler, Dean F. Bajorin, Robert Dreicer, Daniel J. George, Matthew I. Milowsky, Dan Theodorescu, David J. Vaughn, Matthew D. Galsky, Mark S. Soloway & David I. Quinn. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings. European Urology 63:1, pages 58-66.
Crossref
Crossref
Jong-Mu Sun, Ji-Youn Sung, Se Hoon Park, Ghee Young Kwon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Jisuk Jo, Han Yong Choi & Ho Yeong Lim. (2012) ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer 12:1.
Crossref
Crossref
Derek Raghavan, Earle Burgess, Kris E. Gaston, Michael R. Haake & Steven B. Riggs. (2012) Neoadjuvant and Adjuvant Chemotherapy Approaches for Invasive Bladder Cancer. Seminars in Oncology 39:5, pages 588-597.
Crossref
Crossref
Amber M. D’Souza, Kamal S. Pohar, Tahir Arif, Susan Geyer & Debra L. Zynger. (2012) Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Archiv 461:4, pages 467-474.
Crossref
Crossref
Joshua J. Meeks, Joaquim Bellmunt, Bernard H. Bochner, Noel W. Clarke, Siamak Daneshmand, Matthew D. Galsky, Noah M. Hahn, Seth P. Lerner, Malcolm Mason, Thomas Powles, Cora N. Sternberg & Guru Sonpavde. (2012) A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology 62:3, pages 523-533.
Crossref
Crossref
Robert Rosenblatt, Amir Sherif, Erkki Rintala, Rolf Wahlqvist, Anders Ullén, Sten Nilsson & Per-Uno Malmström. (2012) Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer. European Urology 61:6, pages 1229-1238.
Crossref
Crossref
Guru Sonpavde & Cora N. Sternberg. (2012) Neoadjuvant Chemotherapy for Invasive Bladder Cancer. Current Urology Reports 13:2, pages 136-146.
Crossref
Crossref
Jørgen Bjerggaard Jensen, Benedicte Parm Ulhøi & Klaus Møller‐Ernst Jensen. (2011) Extended versus limited lymph node dissection in radical cystectomy: Impact on recurrence pattern and survival. International Journal of Urology 19:1, pages 39-47.
Crossref
Crossref
Haruhito Azuma, Teruo Inamoto, Kiyoshi Takahara, Naokazu Ibuki, Hayahito Nomi, Kazuhiro Yamamoto, Yoshihumi Narumi & Takanobu Ubai. (2011) Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: Development of novel bladder preservation approach, Osaka Medical College regimen. International Journal of Urology 19:1, pages 26-38.
Crossref
Crossref
Jason A. Efstathiou, Anthony L. Zietman, John J. Coen & William U. Shipley. 2012. Clinical Radiation Oncology. Clinical Radiation Oncology
1099
1123
.
Seth P. Lerner & Cora N. Sternberg. 2012. Campbell-Walsh Urology. Campbell-Walsh Urology
2355
2374.e6
.
Jorge A. Garcia, Dale R. Shepard & Robert Dreicer. 2012. The Urinary Tract. The Urinary Tract
283
292
.
Nabil Ismaili, Sanaa Elmajjaoui, Youssef Bensouda, Rhizlane Belbaraka, Halima Abahssain, Wafa Allam, Zouhour Fadoukhair, Mohamed Mesmoudi, Rachid Tanz, Tarik Mahfoud, Abdelhamid Elomrani, Mouna Khouchani, Yassir Sbitti, Noureddine Benjaafar, Hassan Errihani & Ali Tahri. (2011) Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?. Oncology Reviews 5:3, pages 185-189.
Crossref
Crossref
Nikhil Vasdev, Matthew B.K. Shaw & Andrew C. Thorpe. (2011) Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Current Urology 5:2, pages 57-61.
Crossref
Crossref
Faysal A. Yafi, Armen G. Aprikian, Joseph L. Chin, Yves Fradet, Jonathan Izawa, Eric Estey, Adrian Fairey, Ricardo Rendon, Ilias Cagiannos, Louis Lacombe, Jean‐Baptiste Lattouf, David Bell, Darrel Drachenberg & Wassim Kassouf. (2010) Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU International 108:4, pages 539-545.
Crossref
Crossref
G. Kaneko, E. Kikuchi, K. Matsumoto, J. Obata, S. Nakamura, A. Miyajima & M. Oya. (2011) Neoadjuvant Gemcitabine Plus Cisplatin for Muscle-invasive Bladder Cancer. Japanese Journal of Clinical Oncology 41:7, pages 908-914.
Crossref
Crossref
N. Ismaili, M. Amzerin, S. Elmajjaoui, J.-P. Droz, A. Flechon & H. Errihani. (2011) Rôle de la chimiothérapie dans la prise en charge du cancer de la vessie. Progrès en Urologie 21:6, pages 369-382.
Crossref
Crossref
Magnus Annerstedt & Alex Mottrie. 2012. Robotic Urologic Surgery. Robotic Urologic Surgery
391
396
.
James Thomasch & Sam S. Chang. 2010. Evidence‐Based Urology. Evidence‐Based Urology
314
320
.
Maha H.A. Hussain, David P. Wood, Dean F. Bajorin, Bernard H. Bochner, Robert Dreicer, Donald L. Lamm, Michael A. O'Donnell, Arlene O. Siefker-Radtke, Dan Theodorescu & Colin P. Dinney. (2009) Bladder Cancer: Narrowing the Gap Between Evidence and Practice. Journal of Clinical Oncology 27:34, pages 5680-5684.
Crossref
Crossref
Joshua F. Coleman & Donna E. Hansel. (2009) Utility of Diagnostic and Prognostic Markers in Urothelial Carcinoma of the Bladder. Advances in Anatomic Pathology 16:2, pages 67-78.
Crossref
Crossref
Fabio Calabrò & Cora N. Sternberg. (2009) Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. European Urology 55:2, pages 348-358.
Crossref
Crossref
Satoshi Washino, Masaru Hirai, Fumihito Terauchi, Atsushi Matsuzaki, Yutaka Kobayashi & Katsuhiko Matsuura. (2009) INTRA-ARTERIAL CHEMOTHERAPY FOR BLADDER PRESERVATION IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER. The Japanese Journal of Urology 100:3, pages 486-494.
Crossref
Crossref
Frank vom Dorp, Andreas Eisenhardt, Peter-Jürgen Goebell, Jürgen Gschwend, Tobias Jäger, Gerhard Jakse, Dieter Jocham, A. Karl, S. Krege, G. Lümmen, Thomas Otto, Albert Rettenmeier, Claus Rödel, Herbert Rübben, Marcus Schenck, Kurt Werner Schmid, Christian Stief, Michael Stöckle & Dirk Zaak. 2009. Uroonkologie. Uroonkologie
395
476
.
Karen Giselle Chee & Primo N. Lara. 2010. Bladder Cancer. Bladder Cancer
231
237
.
Faysal A. Yafi, Jordan R. Steinberg & Wassim Kassouf. (2008) Contemporary management of muscle-invasive bladder cancer. International Journal of Clinical Oncology 13:6, pages 504-509.
Crossref
Crossref
Matthew I. Milowsky, Walter M. Stadler & Dean F. Bajorin. (2008) Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle‐invasive bladder cancer. BJU International 102:9b, pages 1339-1344.
Crossref
Crossref
Jadwiga NOWAK-SADZIKOWSKA, Teresa KOWALSKA, Jerzy JAKUBOWICZ & Teresa SZPYTMA. (2008) Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity.. Reports of Practical Oncology & Radiotherapy 13:6, pages 300-308.
Crossref
Crossref
. 2008. Treatment and Management of Bladder Cancer. Treatment and Management of Bladder Cancer
211
217
.
Daniel Y. C. Heng & Jorge A. Garcia. (2008) High-risk bladder cancer: improving outcomes with perioperative chemotherapy. Oncology Reviews 2:1, pages 4-8.
Crossref
Crossref
James S. Butler. 2008. Radiation Oncology. Radiation Oncology
283
298
.
H. Suttmann, J. Lehmann & M. Stöckle. (2007) Adjuvante und neoadjuvante Chemotherapie beim HarnblasenkarzinomAdjuvant and neoadjuvant chemotherapy for bladder cancer. Der Onkologe 13:12, pages 1101-1108.
Crossref
Crossref
Cora N. Sternberg. (2007) Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer to Enhance Survival and/or as a Strategy for Bladder Preservation. Seminars in Oncology 34:2, pages 122-128.
Crossref
Crossref
Cora N. Sternberg, S. Machele Donat, Joaquim Bellmunt, Randall E. Millikan, Walter Stadler, Pieter De Mulder, Amir Sherif, Hans von der Maase, Taiji Tsukamoto & Mark S. Soloway. (2007) Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. Urology 69:1, pages 62-79.
Crossref
Crossref
F. vom Dorp, A. Eisenhardt, P.J. Goebell, J. Gschwend, T. Jäger, G. Jakse, D. Jocham, S. Krege, G. Lümmen, T. Otto, A. Rettenmeier, C. Rödel, H. Rübben, R. Sauer, M. Schenck, K.W. Schmid, C. Stief, M. Stöckle & D. Zaak. 2007. Uroonkologie. Uroonkologie
301
372
.
Peter C. Black, Gordon A. Brown, H. Barton Grossman & Colin P. Dinney. (2006) Neoadjuvant chemotherapy for bladder cancer. World Journal of Urology 24:5, pages 531-542.
Crossref
Crossref
Shahrokh F. Shariat, Pierre I. Karakiewicz, Ganesh S. Palapattu, Gilad E. Amiel, Yair Lotan, Craig G. Rogers, Amnon Vazina, Patrick J. Bastian, Amit Gupta, Arthur I. Sagalowsky, Mark Schoenberg & Seth P. Lerner. (2006) Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. Clinical Cancer Research 12:22, pages 6663-6676.
Crossref
Crossref
CORA N. STERNBERG & LAURENCE COLLETTE. (2006) WHAT HAS BEEN LEARNED FROM META‐ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER?. BJU International 98:3, pages 487-489.
Crossref
Crossref
C.N. Sternberg. (2006) Muscle invasive and metastatic bladder cancer. Annals of Oncology 17, pages x23-x30.
Crossref
Crossref
R. Sawhney, D. Bourgeois & U.B. Chaudhary. (2006) Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. Annals of Oncology 17:9, pages 1360-1369.
Crossref
Crossref
Guru Sonpavde, Thomas E. Hutson & William R. Berry. (2006) Systemic Chemotherapy for Urothelial Cancer. Clinical Genitourinary Cancer 5:1, pages 34-42.
Crossref
Crossref
Seth M. Cohen, Anupama Goel, John Phillips, Ronald D. Ennis & Michael L. Grossbard. (2006) The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer. The Oncologist 11:6, pages 630-640.
Crossref
Crossref
P. J. Goebell, F. vom Dorp & H. Rübben. (2006) Stellenwert der systemische Chemotherapie des HarnblasenkarzinomsValue of systemic chemotherapy in bladder cancer. Der Urologe 45:5, pages 586-593.
Crossref
Crossref
Mahesh C. Goel, Surena F. Matin, Ithaar Derweesh, Howard Levin, Stevan Streem & Andrew C. Novick. (2006) Partial nephrectomy for renal urothelial tumors: Clinical update. Urology 67:3, pages 490-495.
Crossref
Crossref
Guru Sonpavde & Daniel P. Petrylak. (2006) Perioperative chemotherapy for bladder cancer. Critical Reviews in Oncology/Hematology 57:2, pages 133-144.
Crossref
Crossref
Fredrik Liedberg & Wiking Månsson. (2006) Lymph Node Metastasis in Bladder Cancer. European Urology 49:1, pages 13-21.
Crossref
Crossref
Cheryl T. Lee, Brent Hollenbeck & David P. WoodJr.Jr.. 2006. Oncology. Oncology
813
832
.
J. Lehmann, M. Retz & M. Stöckle. (2005) Systemische Therapie des fortgeschrittenen UrothelkarzinomsSystemic chemotherapy for advanced urothelial carcinoma. Der Onkologe 11:11, pages 1210-1218.
Crossref
Crossref
J.A. NIEUWENHUIJZEN, A. BEX, W. MEINHARDT, J.M. KERST, J.H. SCHORNAGEL, H. VAN TINTEREN & S. HORENBLAS. (2005) NEOADJUVANT METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN FOR HISTOLOGICALLY PROVEN LYMPH NODE POSITIVE BLADDER CANCER. Journal of Urology 174:1, pages 80-84.
Crossref
Crossref
Dimitrios Pectasides, Melina Pectasides & Maria Nikolaou. (2005) Adjuvant and Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Literature Review. European Urology 48:1, pages 60-68.
Crossref
Crossref
J. Simon, J. E. Gschwend & B. G. Volkmer. (2005) Lokalrezidiv nach radikaler Zystektomie bei HarnblasenkarzinomLocal recurrence following radical cystectomy for bladder cancer. Der Urologe, Ausgabe A 44:4, pages 375-381.
Crossref
Crossref
Jorge A Garcia & Robert Dreicer. (2005) Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nature Clinical Practice Urology 2:1, pages 32-37.
Crossref
Crossref
K. Possinger, A. Schauer, F. Griesinger & A. C. Roever. 2005. The Sentinel Lymph Node Concept. The Sentinel Lymph Node Concept
503
551
.
J Erik Busby & Christopher P Evans. (2004) Old friends, new ways: revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes. Current Opinion in Urology 14:5, pages 251-257.
Crossref
Crossref
John D Chester, Geoffrey D Hall, Martin Forster & Andrew S Protheroe. (2004) Systemic chemotherapy for patients with bladder cancer – current controversies and future directions. Cancer Treatment Reviews 30:4, pages 343-358.
Crossref
Crossref
Amir Sherif, Lars Holmberg, Erkki Rintala, Oddvar Mestad, Jonas Nilsson, Sten Nilsson & Per-Uno Malmström. (2004) Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic Studies. European Urology 45:3, pages 297-303.
Crossref
Crossref
Markus A. Kuczyk, Reinhold Zimmermann, Axel Merseburger, Ares Anastasiadis, Stefan Corvin, J.T. Hartmann & Arnulf Stenzl. (2004) Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. European Urology Supplements 3:3, pages 79-88.
Crossref
Crossref
. (2004) Neo-adjuvant chemotherapy for invasive bladder cancer. Cochrane Database of Systematic Reviews 2012:2.
Crossref
Crossref
C Vale. (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. The Lancet 361:9373, pages 1927-1934.
Crossref
Crossref